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Abstract
Critical limb ischemia (CLI) is an advanced form of peripheral artery disease which is responsible
for approximately 100,000 amputations per year in the US. Trials to date have reported clinical
improvement and reduced need for amputation in CLI patients receiving autologous bone marrow
or mobilized peripheral blood stem cells for stimulation of angiogenesis. While such treatments are
currently entering Phase III trials, practical and scientific pitfalls will limit widespread
implementation if efficacy is proven. Hurdles to be overcome include: a) reduced angiogenic
potential of autologous cells in aged patients with cardiovascular risk factors; b) invasiveness/
adverse effects of bone marrow extraction and G-CSF mobilization, respectively; and c) need for
on-site cellular manipulation. The Endometrial Regenerative Cell (ERC) is a mesenchymal-like stem
cell derived from the menstrual blood that is believed to be associated with endometrial
angiogenesis. We discuss the possibility of using allogeneic ERCs as an "off the shelf" treatment for
CLI based on the following properties: a) High levels of growth factors and matrix metalloprotease
production; b) Ability to inhibits inflammatory responses and lack of immunogenicity; and c)
Expandability to great quantities without loss of differentiation ability or karyotypic abnormalities.
Critical limb ischemia
Critical limb ischemia (CLI) is classically defined as
chronic ischemic rest pain, ulcers, or gangrene due to
proven occlusive disease [1]. It is diagnosed based on
symptomology such as burning rest pain in the distal foot
or lack of foot pulses, as well as using objective measure-
ments including low ankle pressure (< 50–70 mm Hg),
reduced toe pressure (< 30–50 mm Hg), reduced transcu-
taneous oxygen (TPCO2 (< 30–50 mm Hg) and ankle bra-
chial index (ABI) of < 0.6. Occlusion is demonstrated by
angiography or duplex ultrasound scanning. CLI is caused
by arterial occlusion affecting the limbs, usually caused by
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atherosclerosis or in a smaller number of patients by
thromboangiitis obliterans (Buerger's Disease), or arteri-
tis.
This condition is a major cause of morbidity and mortal-
ity: Approximately 20–45% of patients require amputa-
tion, and 1-year mortality is estimated to be as high as
45% in patients who have undergone amputation [2]. The
quality of life of CLI patients has been compared by some
authors to that of terminal cancer patients [3]. Current
treatment options for this group of patients are limited.
According to the Inter-Society Consensus for the Manage-
ment of Peripheral Arterial Disease (TASC II) treatment
for CLI should be focused on revasularization using surgi-
cal or percutanous means [1]. Unfortunately less than half
of the patients are eligible for these procedures, and effi-
cacy is limited. Additionally, many patients require addi-
tional procedures due to high levels of restenosis. Non-
surgical options for CLI are limited to medical therapy,
which offers limited or no benefit. The dismal state of
options for this patient population was best surmised by
Schainfeld and Isner in the statement "Critical limb
ischemia: nothing to give at the doctors office" [4]. Given
the poor prognosis associated with CLI, numerous inter-
ventions have been attempted, primarily based on stimu-
lation of angiogenesis in order to allow formation of
collateral blood vessels.
Cytokine mediated angiogenesis for CLI
Angiogenesis therapy has been described as a "biological
bypass", the idea being that through administration of
agents capable of inducing collateralization, a more natu-
ral type of "bypass" can be achieved. Indeed it has been
observed that ischemic muscles secrete angiogenic factors
in response to hypoxia and that to some extent natural
angiogenesis does occur in animal models of CLI and in
humans [5,6]. One of the angiogenic factors noted in
many ischemic conditions, including cardiac ischemia,
stroke, and CLI is vascular endothelial growth factor
(VEGF) [7-9]. In 1994, Isner's group sought to enhance
ischemia-associated angiogenesis using single bolus intra-
arterial administration of VEGF-165 in a rabbit model of
CLI. Rabbits with resected femoral arteries demonstrated
augmentation of perfusion, increased capillary density,
and overall better function as compared to control rabbits
[10]. Subsequent experiments sought to optimize thera-
peutic effect using different dosing schedules. Daily VEGF-
165 administration for 10 days subsequent to ligation and
resection of the external iliac artery and femoral artery,
respectively was performed [11]. Not only was dose-
dependent increase in collateralization observed, but rab-
bits receiving the highest dose of VEGF-165 (1 mg) had no
incidence of calf muscle atrophy and distal limb necrosis,
whereas this was present in 85.7% of control rabbits. A
similar study in the rabbit model of CLI demonstrated
superior benefit in terms of limb function in animals
receiving VEGF by osmotic pump for 28-days in compari-
son to nitroglycerin or saline treatment [12]. A variety of
studies have been performed with VEGF protein which
confirmed the proangiogenic, as well as angiogenesis-
independent muscle reparative properties in the limb
ischemia model [13-15]. These positive preclinical data
unfortunately were not successfully reproduced in the
clinic. Trials using VEGF protein [16], or DNA, did not
show significant benefit at reducing leg amputations in a
double blind setting [15,17]. One of the concerns with
VEGF therapy is its vasodilatory effects, as well as induc-
tion of blood vessels that are relatively immature and
"leaky".
Another approach involved use of the cytokine fibroblast
growth factor-1 (FGF-1). Given that FGF-1 is considered
"upstream" of VEGF, it is believed to stimulate numerous
angiogenic processes so as to result in creation of more
mature vessels [18]. Indeed, it is believed that one of the
differences between tumor neo-vasculature, which is char-
acteristically leaky, and neo-vasculature associated with
physiological angiogenesis, is the ratio of VEGF to FGF
[19]. Specifically, it was demonstrated both in animal
models [20] and in clinical trials [21] that muscular
ischemia is associated with up-regulation of FGF gene
transcription, suggesting that this is part of the endog-
enous pro-angiogenic response to ischemia. The critical
role of FGF in endogenous angiogenesis was conclusively
demonstrated in FGF knockout mice, which displayed
inhibited ability to heal post-wounding [22]. Although
FGF-1 gene therapy has clinically been used in CLI
patients with some improvement in ABI and perfusion,
statistically powered randomized clinical trials have not
been conducted to date [23].
It is known that additive and/or synergistic effects are
observed in terms of neoangiogenesis when several ang-
iogenic factors are combined. For example, Cao et al dem-
onstrated synergy between administration of PDGF-BB
and FGF-2 in terms of increasing blood vessel formation
and function in the femoral artery ligation model in rats
and rabbits [24]. Similarly, in cancer angiogenesis, it is
known that several tumor-derived angiogenic factors syn-
ergize for acceleration of neovascularization [25]. Accord-
ingly, investigators have attempted to activate upstream
mediators of several angiogenic signals through transfec-
tion of genes encoding transcription factors such as HIF-1
alpha [26]. In fact, this approach has been demonstrated
to be superior to VEGF gene administration in terms of
new capillary sprouting. In a Phase I dose-escalating trial,
transfection of HIF-1 alpha into CLI patients demon-
strated tolerability with some indication of efficacy [27].
In conclusion, while administration of angiogenic factors
to patients with CLI does induce some benefit in early tri-
als, data from randomized trials to date do not supportJournal of Translational Medicine 2008, 6:45 http://www.translational-medicine.com/content/6/1/45
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widespread use. The transfection of upstream transcrip-
tion factors such as HIF-1 alpha is a promising approach
since it mimics natural angiogenesis in that a plurality of
growth factors are induced following transfection [26,28].
However clinical results are too premature to draw firm
conclusions. Additionally, the transfection of foreign
genes may possess unintended consequences in the long
run due to the uncontrolled nature of the transfected gene
insert.
Animal studies using stem cell therapy for CLI
Cellular therapy for CLI is based on the rationale that
delivery of endothelial progenitor cells into areas of
ischemia may result not only in differentiation of the cells
into endothelium and thus contribute to angiogenesis,
but also produce various growth factors capable of stimu-
lating angiogenesis through paracrine interactions with
adjacent cells. One of the first observations that bone mar-
row contains high numbers of endothelial progenitor
cells was by Ashara et al using infusion of bone marrow
cells in which the beta-galactosidase marker was expressed
under control of endothelial cell-specific promoters such
as Flk-1 and Tie-2. EPC derived from the genetically
marked bone marrow were shown to promote physiolog-
ical (corpus luteal and wound healing), and pathogenic
(cancer) angiogenesis. The same study demonstrated that
administration of bone marrow cells into muscles of mice
with induced hindlimb ischemia led to neoangiogenesis
mediated in part by the transferred cells [29].
A more extensive investigation of bone marrow adminis-
tration of treatment of a model of CLI utilized the rat fem-
oral ligation model and assessed not only perfusion but
also the functional endpoint of treadmill running.
Administration of syngeneic bone marrow in six locations
proximal to the area of ligation caused a significant
increase in perfusion, as well as treadmill performance in
the treated rats [30]. A study using a similar model dem-
onstrated not only improved perfusion subsequent to
bone marrow administration but also enhanced produc-
tion of the angiogenic cytokines IL-1 and FGF-2 [31].
Since diabetes is associated with CLI, one question
addressed in animal experiments is whether the diabetic
state influences angiogenic ability of autologous bone
marrow cells. Using the femoral artery ligation model, it
was demonstrated that cellular therapy was able to suc-
cessfully induce angiogenesis in streptozoicin treated dia-
betic rats [32]. Subsequent to these experiments,
numerous variations on a theme have been performed, all
illustrating the ability of bone marrow and other cellular
populations to induce therapeutic angiogenesis in animal
models. For example, implantation of whole bone mar-
row was effective at inducing formation of collateraliza-
tion in a model of CLI involving double ligation of the left
femoral artery just distal to the profunda femoral artery
branch. Angiogenesis was demonstrated by histology and
presence of endothelial cells possessing donor-specific
marker [33]. Cumulatively, animal studies demonstrated
that stem cells of a wide variety of sources are capable of
both generating angiogenic cytokines that promote
endogenous stem cells and reparative processes, and
directly promote angiogenesis via EPCs. The next question
was whether this could be translated into clinical applica-
tions.
Clinical use of stem cell therapy for CLI
Bone marrow transplantation has been clinically used for
hematopoietic reconstitution for more than 40 years, thus
procedures for bone marrow extraction and manipulation
are routine. In 2002 Tateishi-Yuyama et al [34] used the
technique of bone marrow extraction and mononuclear
cell preparation to generate an autologous source of stem
cells for CLI treatment. In total 45 patients were injected
with mononuclear cells at concentrations ranging
between 0.7–2.8 × 109 cells in the gastrocnemius muscle
of the ischemic leg using approximately 40 injections in a
volumes of 0.75 ml. Statistically significant increases in
ankle brachial index, trancutaneous oxygen pressure, pain
free walking time, and amelioration of rest pain were
detected at 4 and 24-week follow-up. The investigators
also demonstrated production of proangiogenic cytokines
by the injected cells. Other groups also reported similar
therapeutic results: Nizankowski et al treated 10 CLI
patients with condensed bone marrow stem cells and
observed improvement using laser doppler flux and per-
cutaneous oxygen partial pressure, as well as decrease in
pain severity. Interestingly no correlation was found
between cell number injected and effect [35]. Durdu et al
performed intramuscular injection of autologous bone
marrow mononuclear cells to 28 CLI patients who were
nonresponders to conservative therapy and ineligible for
revascularization. Of the 28 patients, only 1 needed
amputation. Statistically significant increases in rest pain
scores, peak walking time, and quality of life were noted.
Angiography evidence of collateral vessel formation was
observed in 22 of the patients at 6 months [36]. Numer-
ous other studies have demonstrated safety and efficacy of
autologous bone marrow stem cell therapy [37,38], as
well as for autologous mobilized stem cells [39-41]. A
review of the total 18 clinical studies published in the Eng-
lish language using autologous stem cell therapy for CLI
overviews the above mentioned studies in detail [42].
Thus, autologous bone marrow therapy for CLI appears to
be a promising solution to the current lack of treatments
in patients ineligible for endovascular/surgical interven-
tions. However, this is limited by the need for anesthesia
during the bone marrow extraction procedure, which is
dangerous in the CLI population since numerous co-mor-
bidities exist [43]. Mobilization using G-CSF alleviates theJournal of Translational Medicine 2008, 6:45 http://www.translational-medicine.com/content/6/1/45
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need for bone marrow puncture, however use of this
cytokine is feared by some to predispose CLI patients to
thrombosis due to the potent leukocyte mobilization that
occurs subsequent to its administration [44].
Additionally, there are suggestions in the literature that
endothelial progenitors from bone marrow of patients
with peripheral artery disease may be suboptimal in com-
parison to other progenitor sources [45,46]. Specifically,
these findings suggest firstly that an age-associated decline
in angiogenic potential of bone marrow cells occurs, and
secondly, patients with peripheral artery disease have a
significantly inhibited angiogenic potential as compared
with age-matched controls. One explanation for this is
that stem cell depletion occurs due to increased demand
for new progenitor cells in the damaged vasculature [47].
An "off the shelf" product that is collected from young
volunteers and selected for potent angiogenic activity may
overcome this drawback.
Endometrial regenerative cells
Dr Taylor's group demonstrated that various endometrial
cells are actually derived from bone marrow. Through
studying endometrial stromal cells isolated from female
recipients of male bone marrow, they reported positive
staining for the Y-chromosome in a substantial number of
cells [48]. Reports of adherent, STRO-1 positive cells that
can be isolated from the endometrium have been made by
Dr. Taylor and other groups as well [49-51]. Given the
high rate of angiogenesis associated with build up of the
uterine lining, it is known that various proangiogenic cells
and possibility EPC are found. We have reported a unique
population of cells derived from the menstrual blood,
which after cloning we termed Endometrial Regenerative
Cells (ERC) [52]. We believe the ERC represents a unique
population of cells in contrast to endometrial stromal
cells based on: a) different rate of proliferation (ERC pro-
liferate approximately once every 19 hours, whereas stro-
mal cells every 24–36 hours); b) ability to differentiate
into a wide number of tissues, stromal cells have only
been shown to differentiate into bone, fat, and cartilage;
c) ERC lack expression of STRO-1, whereas other stromal
derived cells express this marker.
Cells resembling some phenotypic characteristics of ERC
appear to be similar to the menstrual blood derived mes-
enchymals described by Miyoshi's group [53]. These cells
express CD29, CD105 and are negative for CD34 and
CD45. The investigators demonstrated cardiogenic poten-
tial of these cells both in vitro and in vivo, without obser-
vation of carcinogenic changes. Patel's group reported a
"multipotent menstrual blood stromal stem cell" [54],
which had an expression profile of Oct-4, c-kit and SSEA-
4 positive and negative for expression of hematopoietic
markers. Given that menstrual blood contains numerous
types of cellular populations, it is possible that each of
these two other groups have cells that are unique, however
express certain commonalities. Regardless of differences,
all three groups have demonstrated safety in terms of lack
of teratogenic potential, some degree of pluripotency, and
ability to be rapidly expanded in tissue culture.
Angiogenic potential of ERC
The endometrium undergoes rapid angiogenesis in a con-
trolled manner monthly. Upregulated production of ang-
iogenic factors including PDGF, EGF, and VEGF have been
described both in the mouse and human endometrium
[55,56]. Some degree of similarity exists between ERC and
bone marrow derived mesenchymal stem cells, for exam-
ple, expression of CD90, CD105 and lack of CD45 and
CD34 [57]. Bone marrow derived mesenchymal stem cells
are potently angiogenic [58]. Therefore we performed a
series of preliminary experiments assessing proof of con-
cept of angiogenic activity. Given that conditioned media
from pro-angiogenic cells has previously been demon-
strated to stimulate HUVEC proliferation [59], we used
this assay to assess soluble angiogenic activity. As seen in
Figure 1, a dose dependent stimulation of HUVEC prolif-
eration was observed. This is in agreement with our previ-
ous publication demonstrating potent secretion of
angiogenic cytokines such as PDGF-BB and angiopoietin
[52]. In order to assess in vivo angiogenic activity, a pilot
study involving 8 treated and 8 control mice was per-
formed. All animals were cared for in accordance with the
guidelines established by the Canadian Council on Ani-
mal Care. Immune competent BALB/c mice were admin-
istered approximately 1 million ERC intramuscularly after
ligation of the femoral artery and its branches (superficial
Stimulation of HUVEC proliferation by ERC conditioned  media Figure 1
Stimulation of HUVEC proliferation by ERC condi-
tioned media. ERC conditioned media was generated by 5 
day culture of 10 × 10(5) cells in completed DMEM media. 
Conditioned media was added at the indicated concentra-
tions to HUVEC cells in 96 well plates at a concentration of 
5000 cells per well. Cells were incubated for 72 hours and 
proliferation as assessed by thymidine incorporation. Error 
bars represent ± Standard Deviation.Journal of Translational Medicine 2008, 6:45 http://www.translational-medicine.com/content/6/1/45
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epigastrlc artery) for induction of the limb ischemia.
Additionally, excision of N. peroneus for reproducing a
neurotrophic ulcer-like injury was performed. Mice were
divided into 2 groups of 8. Immediately after induction of
injury, 1 million ERC were injected into the hind-limb
muscle below the area of ligation. Cells were also injected
on day 0, day 2 and day 4. ERC where injected in a volume
of 200 microliters of saline. By day 14, necrosis was
observed in legs of 8 control mice. 8 mice treated with
ERC had intact limbs, with 2 displaying signs of impeded
walking. Figure 2 depicts a representative control and
treated mouse. These data, although preliminary, suggest
that possibility of using ERC to stimulate angiogenesis.
Perhaps most strikingly was that the therapeutic effect was
observed despite utilization of human cells in an immune
competent xenogeneic animal.
Allogeneic barriers
Mesenchymal stem cell populations appear to possess
active immune modulatory properties in vitro and in vivo.
Specifically, bone marrow derived mesenchymal cells
have been demonstrated to inhibit ongoing mixed lym-
phocyte reaction (MLR) [60], induce generation of T reg-
ulatory cells [61], and in vivo suppress autoimmunity
such as collagen induced arthritis [62] and experimental
allergic encephalomyelitis [63]. In animal models, accel-
eration of wound healing [64], or post-infarct recovery
[65], may be accomplished by administration of alloge-
neic mesenchymal cells. Allogeneic cord blood derived
mesenchymal stem cells have demonstrated clinical bene-
fit in a small series of patients with CLI caused by
Buerger's Disease [66]. Perhaps most convincingly, alloge-
neic bone marrow derived mesenchymal stem cells have
passed Phase I clinical trials (safety) and Phase II (prelim-
inary efficacy) and now are in Phase III trials for graft ver-
sus host disease and Crohn's by the company Osiris
Therapeutics [67]. Thus there appears to be support for
the allogeneic use of bone marrow derived mesenchymal
cells for various applications. The question is whether
ERC possess similar immune modulatory properties. This
is particularly important since in many situations autolo-
gous ERC will either not be available or will not be practi-
cal.
In preliminary experiments we have demonstrated that
addition of ERC to ongoing mixed lymphocyte reactions
results in suppression of proliferation (Figure 3a), inhibi-
tion of IFN-gamma (Figure 3b), stimulation of IL-4 (fig-
ure 3c) and inhibition of TNF-alpha after LPS stimulation
(Figure 3d). These results support the notion that ERC
may share immune modulatory properties with bone
marrow derived mesenchymal stem cells. Back to back
comparisons between ERC and bone marrow derived
MSC have demonstrated equivalent, or in some cases,
superior immunomodulatory potential based on inhibi-
tion of mixed lymphocyte reaction.
Clinical entry of ERC
Clinical entry of novel cellular therapies requires demon-
stration of safety and reasonable possibility of improving
the patient's condition. Previous studies involving long
term follow up of animals treated with ERC, as well as
karyotypic normality of these cells after extended passage
(68 doublings) have demonstrated lack of tumorogenicity
[52]. In fact, administration of ERC into 18 SKH1 treated
with 2240 J/m2 UVB radiation three times a week for 10
weeks to induce skin tumors did not accelerate tumor for-
mation. Based on what appears to be a favorable safety
profile, as well as preliminary supportive data, we propose
a dose escalating clinical trial evaluating intramuscular
administration of ERC in patients with CLI ineligible for
surgical or endovascular intervention. Given several bio-
logical similarities between bone marrow derived mesen-
chymal stem cells and ERC, as well as side-by-side growth
factor production data, dose escalation may be performed
from 10, 25, and 50 million cells per limb. One unique
aspect of using ERC for this indication is the possibility of
administering allogeneic, standardized cell populations.
In addition to classical endpoints of success in CLI trials
such as imaging for collateral vessel formation, pain free
walking, ABI, and Fountain Score, ERC trials should
include serum cytokine production and evaluation of
Limb preservation by ERC administration Figure 2
Limb preservation by ERC administration. 16 BALB/c 
female mice (6–8 weeks of age, Jackson Labs, Bar Harbor, 
Maine) underwent unilateral ligation of the femoral artery 
and its branches (superficial eplgastrlc artery) for induction of 
the limb ischemia. Additionally, ligation of N. peroneus for 
reproducing a neurotrophic ulcer-like injury was performed. 
Mice were divided into 2 groups of 8. Immediately after 
induction of injury, 1 million ERC were injected into the 
hind-limb muscle below the area of ligation. Cells were also 
injected on day 0, day 2 and day 4. ERC where injected in a 
volume of 200 microliters of saline. By day 14, necrosis was 
observed in legs of 8 control mice. 8 mice treated with ERC 
had intact limbs, with 2 displaying signs of impeded walking.Journal of Translational Medicine 2008, 6:45 http://www.translational-medicine.com/content/6/1/45
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endogenous stem cell mobilization. In conclusion, the
ERC represents a novel approach the CLI by offering an
"off the shelf" therapeutic that circumvents pitfalls of
other approaches currently in use. The proposed clinical
trial will shed light of the viability of this hypothesis.
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